Martí-Carvajal Arturo J, Martí-Amarista Cristina Elena
Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE (Cochrane Ecuador), Quito, Ecuador.
School of Medicine, Universidad Francisco de Vitoria (Cochrane Madrid), Madrid, Spain.
Cochrane Database Syst Rev. 2020 Jun 22;6(6):CD010985. doi: 10.1002/14651858.CD010985.pub4.
Sickle cell disease is the most common hemoglobinopathy occurring worldwide and sickle cell intrahepatic cholestasis is a complication long recognized in this population. Cholestatic liver diseases are characterized by impaired formation or excretion (or both) of bile from the liver. There is a need to assess the clinical benefits and harms of the interventions used to treat intrahepatic cholestasis in people with sickle cell disease. This is an update of a previously published Cochrane Review.
To assess the benefits and harms of the interventions for treating intrahepatic cholestasis in people with sickle cell disease.
We searched the Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register, which comprises references identified from comprehensive electronic database searches and handsearching of relevant journals and abstract books of conference proceedings. We also searched the LILACS database (1982 to 21 January 2020), the WHO International Clinical Trials Registry Platform Search Portal and ClinicalTrials.gov (21 January 2020). Date of last search of the Cochrane Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register: 25 November 2019.
We searched for published or unpublished randomised controlled trials.
Each author intended to independently extract data, assess the risk of bias of the trials by standard Cochrane methodologies and assess the quality of the evidence using the GRADE criteria; however, no trials were included in the review.
We did not identify any randomised controlled trials.
AUTHORS' CONCLUSIONS: This updated Cochrane Review did not identify any randomised controlled trials assessing interventions for treating intrahepatic cholestasis in people with sickle cell disease. Randomised controlled trials are needed to establish the optimum treatment for this condition.
镰状细胞病是全球最常见的血红蛋白病,镰状细胞性肝内胆汁淤积是该人群中长期公认的一种并发症。胆汁淤积性肝病的特征是肝脏胆汁形成或排泄(或两者)受损。有必要评估用于治疗镰状细胞病患者肝内胆汁淤积的干预措施的临床益处和危害。这是对先前发表的Cochrane系统评价的更新。
评估治疗镰状细胞病患者肝内胆汁淤积的干预措施的益处和危害。
我们检索了囊性纤维化和遗传疾病组的血红蛋白病试验注册库,该注册库包括从全面的电子数据库检索以及对相关期刊和会议论文摘要集的手工检索中识别出的参考文献。我们还检索了LILACS数据库(1982年至2020年1月21日)、世界卫生组织国际临床试验注册平台搜索门户和ClinicalTrials.gov(2020年1月21日)。Cochrane囊性纤维化和遗传疾病组血红蛋白病试验注册库的最后检索日期:2019年11月25日。
我们检索已发表或未发表的随机对照试验。
每位作者打算独立提取数据,采用标准的Cochrane方法评估试验的偏倚风险,并使用GRADE标准评估证据质量;然而,该评价未纳入任何试验。
我们未识别出任何随机对照试验。
这项更新的Cochrane系统评价未识别出任何评估治疗镰状细胞病患者肝内胆汁淤积干预措施的随机对照试验。需要进行随机对照试验来确定针对这种情况的最佳治疗方法。